Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules solely from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company provides specific proprietary software products, such as GastroPlus, a physiologically-based simulation tool that predicts the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions for compounds administered through intravenous, oral, ocular, or pulmonary routes; ADMET Predictor, an ADME-Tox property prediction, and model building application; MedChem Studio, a multi-purpose cheminformatics platform used for advanced data mining and de novo molecule design; DDDPlus, a simulation program for formulation scientists that predicts the in vitro disintegration and dissolution of solid dosage forms under different experimental conditions;  MedChem Designer, a free chemical sketching product that combines innovative molecule drawing features with fast and accurate ADMET property predictions from ADMET Predictor.

Lancaster, US
Size (employees)
83 (est)+39%
Simulations Plus was founded in 1996 and is headquartered in Lancaster, US
Report incorrect company information

Simulations Plus Office Locations

Simulations Plus has an office in Lancaster and Buffalo
Lancaster, US (HQ)
42505 10th St W
Buffalo, US
110 1780 Wehrle Dr
Show all (2)
Report incorrect company information

Simulations Plus Financials and Metrics

Simulations Plus Financials

Simulations Plus's revenue was reported to be $24.14 m in FY, 2017

Revenue (Q1, 2018)

7.1 m

Gross profit (Q1, 2018)

5.3 m

Gross profit margin (Q1, 2018), %


Net income (Q1, 2018)

1.7 m

EBIT (Q1, 2018)

2.6 m

Market capitalization (3-Mar-2018)

287.7 m

Cash (3-Mar-2018)

7 m
Simulations Plus's current market capitalization is $287.7 m.
USDFY, 2014FY, 2015FY, 2016FY, 2017


11.5 m18.3 m20 m24.1 m

Revenue growth, %


Cost of goods sold

1.6 m4.3 m4.6 m6.3 m

Gross profit

9.8 m14 m15.4 m17.8 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018


4.1 m4.6 m5.9 m4.8 m5.2 m6 m5.4 m5.7 m6.7 m7.1 m

Cost of goods sold

997.7 k1.1 m1.1 m1.1 m1.3 m1.2 m1.3 m1.6 m1.4 m1.7 m

Gross profit

3.1 m3.4 m4.8 m3.8 m3.9 m4.8 m4.1 m4.2 m5.3 m5.3 m

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016FY, 2017


8.6 m8.6 m8 m6.2 m

Accounts Receivable

8 m(876.2 k)


188.2 k381.7 k410.8 k459.9 k

Current Assets

11.5 m11.5 m12.9 m12.7 m
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018


5.8 m6.1 m6.4 m7.2 m7.1 m7.3 m8.8 m7.4 m8.2 m7 m

Current Assets

10.7 m10.7 m11.8 m12.4 m12.5 m13.6 m13.6 m14 m14.9 m14 m


518.4 k460.3 k420.6 k364.5 k317 k297.4 k272 k280.6 k257.6 k305.6 k


4.8 m4.8 m4.8 m4.8 m4.8 m4.8 m4.8 m4.8 m4.8 m10.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3 m3.8 m5 m5.8 m


192.2 k459.9 k

Accounts Payable

146 k(15.5 k)19.4 k(101.3 k)99.3 k

Cash From Operating Activities

5.3 m7.1 m5.4 m6.9 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

528.9 k970.2 k1.9 m1.1 m2.3 m1.9 m1.4 m1.2 m2.1 m1.7 m

Accounts Payable

235.4 k306.7 k177.4 k153.2 k120.7 k133.1 k(119.3 k)(83.3 k)185 k211.8 k221.4 k211.6 k(99.1 k)

Cash From Operating Activities

(360.1 k)652.4 k2.6 m

Purchases of PP&E

(1.2 k)(2.5 k)(47.3 k)
USDY, 2017


85.2 k

Financial Leverage

1.5 x
Show all financial metrics
Report incorrect company information